Hyason

Hyason is a prescription‑only medicinal product that contains the enzyme hyaluronidase as its active ingredient. It is supplied in an injectable form for intramuscular administration and is marketed in the European Union. Hyaluronidase functions as an adjunctive therapy, helping to modify tissue permeability to improve the dispersion of co‑administered agents. Hyason does not contain a listed strength, and its dosage form is not specified in the public data.

Hyason is employed as an adjunctive enzyme to enhance the delivery and effectiveness of other therapeutic agents administered by injection.

- Facilitates rapid dispersion and absorption of co‑administered drugs such as local anesthetics, antibiotics, or chemotherapeutic agents. - Improves the efficacy of subcutaneous fluid therapy by reducing tissue resistance. - Assists in the distribution of radiopaque contrast media during imaging procedures. - Supports the breakdown of hyaluronic acid accumulations in certain ophthalmic or dermatologic applications. - Used to enhance the spread of agents in regional anesthesia techniques.

Adverse reactions to Hyason are generally related to its enzymatic activity and the injection site, and they can range from mild, transient symptoms to rare but serious systemic events.

Common: - Localized erythema, swelling, or mild pain at the injection site. - Transient pruritus or urticaria limited to the area of administration. - Temporary bruising or hematoma formation. - Mild fever or chills occurring within a few hours after injection. - Headache or dizziness not attributable to other causes.

Serious: - Acute systemic hypersensitivity reactions, including anaphylaxis. - Rapid-onset angioedema affecting the face, lips, or airway. - Tissue necrosis or severe ulceration at the injection site. - Severe hypotension or cardiovascular collapse requiring medical intervention.

When using Hyason, healthcare professionals should evaluate patient history and monitor for potential risks associated with its enzymatic action.

- Assess for known hypersensitivity to hyaluronidase or any animal‑derived proteins before administration. - Use caution in patients with a history of severe allergic reactions or anaphylaxis. - Avoid intramuscular injection in areas with compromised circulation or infection. - Adjust or withhold use in pregnant or breastfeeding women until safety data are established. - Monitor vital signs and injection site for signs of systemic or local reactions during and after administration. - Ensure proper aseptic technique to reduce the risk of injection‑site infection.

Hyason may interact with other medications or substances that influence immune response or tissue permeability, requiring careful consideration.

Avoid: - Concurrent use of other hyaluronidase‑containing products, which can increase the risk of excessive tissue breakdown. - Administration with agents that provoke strong histamine release, such as certain contrast media, without appropriate pre‑medication.

Use with caution: - Co‑administration of local anesthetics, as altered absorption may affect onset and duration. - Simultaneous injection of anticoagulants, because increased tissue permeability could enhance bleeding risk. - Use in patients receiving immunotherapy, where immune modulation may be amplified. - Administration together with high‑dose steroids, as altered distribution may modify their local anti‑inflammatory effect.